Novartis delivers solid sales and profit growth. Strong performance of in-market brands supports confidence in mid-term growth outlook

Ad hoc announcement pursuant to Art. 53 LR

  • Q1 sales grew +5% (cc1, +1% USD), core operating income grew +9% (cc, +3% USD)
    • Innovative Medicines (IM) sales grew +4% (cc, +1% USD) and core operating income +5% (cc, 0% USD)
    • Strong performance of key growth brands including Entresto, Kesimpta, Cosentyx and Zolgensma
    • Sandoz sales grew +8% (cc, +2% USD) and core operating income +26% (cc, +21% USD), benefiting from a lower prior year comparison as …
/by